Tetraphase Pharmaceuticals Inc (TTPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH141203D
- Pages: 49
- November 2018
- Total Views:1152
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Tetraphase Pharmaceuticals Inc (Tetraphase) is a pharmaceutical company that discovers and develops antibiotic resistance medicines. The company's products under clinical development include eravacycline, TP-271, and TP-6076. It develops products for the treatment of respiratory diseases caused by bacterial biothreat and antibiotic resistant public health pathogens. Tetraphase's eravacycline is used for the treatment of multi-drug resistant (MDR) infections which include MDR gram-negative bacteria. The company offers drugs in therapeutic areas of antibiotics, oncology and inflammatory diseases. It also offers research and creation of tetracycline drugs. Tetraphase is headquartered in Watertown, Massachusetts, the US.
Tetraphase Pharmaceuticals Inc (TTPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Tetraphase Pharma Raises Funds Through Venture Financing 11
Licensing Agreements 12
Everest Medicines Enters into Licensing Agreement with Tetraphase Pharma 12
Equity Offering 13
Tetraphase Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 13
Tetraphase Pharma Raises USD65 Million in Public Offering of Shares 14
Tetraphase Pharmaceuticals Raises USD7.6 Million in Public Offering of Common Stock 16
Tetraphase Pharma Raises USD5.6 Million in Public Offering of Shares 17
Tetraphase Pharma Increase its Size of Public Offering of Shares for USD80 Million 19
Tetraphase Pharma Raises USD173 Million in Public Offering of Shares 20
Tetraphase Pharma Raises USD86.3 Million in Public Offering of Shares 22
Tetraphase Pharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 49 Million 24
Tetraphase Pharma Announces That Underwriters' Of Its IPO Exercise Their Over-Allotment Option 26
Acquisition 28
Tetraphase Pharma May Sell Itself 28
Tetraphase Pharmaceuticals Inc-Key Competitors 30
Tetraphase Pharmaceuticals Inc-Key Employees 31
Tetraphase Pharmaceuticals Inc-Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 02, 2018: Tetraphase Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33
May 03, 2018: Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights 35
Mar 06, 2018: Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones 37
Nov 02, 2017: Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements 39
Aug 02, 2017: Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results 41
Aug 02, 2017: Tetraphase Q2 net loss up 42
May 04, 2017: Tetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights 43
Mar 08, 2017: Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones 44
Corporate Communications 46
Mar 01, 2018: Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer 46
Oct 16, 2017: Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer 47
Other Significant Developments 48
Aug 27, 2018: Tetraphase Pharmaceuticals to participate at upcoming investor conferences 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List Of Figure
List of Figures
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tetraphase Pharma Raises Funds Through Venture Financing 11
Everest Medicines Enters into Licensing Agreement with Tetraphase Pharma 12
Tetraphase Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 13
Tetraphase Pharma Raises USD65 Million in Public Offering of Shares 14
Tetraphase Pharmaceuticals Raises USD7.6 Million in Public Offering of Common Stock 16
Tetraphase Pharma Raises USD5.6 Million in Public Offering of Shares 17
Tetraphase Pharma Increase its Size of Public Offering of Shares for USD80 Million 19
Tetraphase Pharma Raises USD173 Million in Public Offering of Shares 20
Tetraphase Pharma Raises USD86.3 Million in Public Offering of Shares 22
Tetraphase Pharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 49 Million 24
Tetraphase Pharma Announces That Underwriters' Of Its IPO Exercise Their Over-Allotment Option 26
Tetraphase Pharma May Sell Itself 28
Tetraphase Pharmaceuticals Inc, Key Competitors 30
Tetraphase Pharmaceuticals Inc, Key Employees 31
Tetraphase Pharmaceuticals Inc, Subsidiaries 32
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Tetraphase Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Tetraphase Pharmaceuticals Inc (Tetraphase) is a pharmaceutical company that discovers and develops antibiotic resistance medicines. The company's products under clinical development include eravacycline, TP-271, and TP-6076. It develops products for the treatment of respiratory diseases caused by bacterial biothreat and antibiotic resistant public health pathogens. Tetraphase's eravacycline is used for the treatment of multi-drug resistant (MDR) infections which include MDR gram-negative bacteria. The company offers drugs in therapeutic areas of antibiotics, oncology and inflammatory diseases. It also offers research and creation of tetracycline drugs. Tetraphase is headquartered in Watertown, Massachusetts, the US.
Tetraphase Pharmaceuticals Inc (TTPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Tetraphase Pharma Raises Funds Through Venture Financing 11
Licensing Agreements 12
Everest Medicines Enters into Licensing Agreement with Tetraphase Pharma 12
Equity Offering 13
Tetraphase Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 13
Tetraphase Pharma Raises USD65 Million in Public Offering of Shares 14
Tetraphase Pharmaceuticals Raises USD7.6 Million in Public Offering of Common Stock 16
Tetraphase Pharma Raises USD5.6 Million in Public Offering of Shares 17
Tetraphase Pharma Increase its Size of Public Offering of Shares for USD80 Million 19
Tetraphase Pharma Raises USD173 Million in Public Offering of Shares 20
Tetraphase Pharma Raises USD86.3 Million in Public Offering of Shares 22
Tetraphase Pharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 49 Million 24
Tetraphase Pharma Announces That Underwriters' Of Its IPO Exercise Their Over-Allotment Option 26
Acquisition 28
Tetraphase Pharma May Sell Itself 28
Tetraphase Pharmaceuticals Inc-Key Competitors 30
Tetraphase Pharmaceuticals Inc-Key Employees 31
Tetraphase Pharmaceuticals Inc-Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 02, 2018: Tetraphase Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33
May 03, 2018: Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights 35
Mar 06, 2018: Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones 37
Nov 02, 2017: Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements 39
Aug 02, 2017: Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results 41
Aug 02, 2017: Tetraphase Q2 net loss up 42
May 04, 2017: Tetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights 43
Mar 08, 2017: Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones 44
Corporate Communications 46
Mar 01, 2018: Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer 46
Oct 16, 2017: Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer 47
Other Significant Developments 48
Aug 27, 2018: Tetraphase Pharmaceuticals to participate at upcoming investor conferences 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List Of Figure
List of Figures
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tetraphase Pharma Raises Funds Through Venture Financing 11
Everest Medicines Enters into Licensing Agreement with Tetraphase Pharma 12
Tetraphase Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 13
Tetraphase Pharma Raises USD65 Million in Public Offering of Shares 14
Tetraphase Pharmaceuticals Raises USD7.6 Million in Public Offering of Common Stock 16
Tetraphase Pharma Raises USD5.6 Million in Public Offering of Shares 17
Tetraphase Pharma Increase its Size of Public Offering of Shares for USD80 Million 19
Tetraphase Pharma Raises USD173 Million in Public Offering of Shares 20
Tetraphase Pharma Raises USD86.3 Million in Public Offering of Shares 22
Tetraphase Pharma Completes Underwriters' Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 49 Million 24
Tetraphase Pharma Announces That Underwriters' Of Its IPO Exercise Their Over-Allotment Option 26
Tetraphase Pharma May Sell Itself 28
Tetraphase Pharmaceuticals Inc, Key Competitors 30
Tetraphase Pharmaceuticals Inc, Key Employees 31
Tetraphase Pharmaceuticals Inc, Subsidiaries 32
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Tetraphase Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020